Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing new innovations in neuromodulator products for aesthetic and therapeutic indications, has announced it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the SAKURA Phase 3 trials, which is the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar frown lines.

Read more from Revance >>